TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Subjects enrolled in V59P13:~* healthy subjects who have completed the V59P13 study.~Naïve subjects:~* healthy subjects aged-matched with subjects who had completed the V59P13 trial.(currently 16-23 years old).~Exclusion Criteria:~Subjects who had completed the V59P13 study:~* who received any meningococcal vaccine after the V59P13 trial;~* who have had previous confirmed or suspected disease caused by N. meningitidis;~* who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);~* subjects with any serious, acute or chronic progressive disease.~Naïve subjects:~* who previously received any meningococcal vaccine;~* who have had previous confirmed or suspected disease caused by N. meningitidis;~* who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);~* subjects with any serious, acute or chronic progressive disease.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
- Licensed comparator (Type: ACTIVE_COMPARATOR): Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
- Naive (Type: OTHER): Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
- MenACWY-CRM/MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
- Licensed comparator/MenACWY-CRM (Type: EXPERIMENTAL): Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be Japanese and live in Japan~* Must be age 20 to 75 years~* Diagnosed less than or equal to 10 years from time of first visit~Exclusion Criteria:~* Anyone who has received etanercept or TNF-inhibitors such as infliximab or adalimumab in the past~* Patient with other rheumatic diseases or conditions that could predispose the patient to infection~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients below 12year scheduled to undergo adenotonsillectomy whose parents or guardians give consent for recruitment into the study.~Exclusion Criteria:~* Non consenting parents or guardians. Antibiotic use in the week preceding surgery. Patients with co mordities. Known allergies to Co-amoxiclav. Patients who develop complication that warrant change of antibiotic.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous intraoperative Enhancin (Type: EXPERIMENTAL): Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
- Postoperative oral Enhancin. (Type: ACTIVE_COMPARATOR): Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Transfusion Dependent Thalassemia~* If iron between 5-15 mg/g dry liver by SQUID, subject must have a documented endocrinopathy or cardiac finding~* Older than 8 years~Exclusion Criteria:~* Participating on another interventional clinical trial

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Exjade) and Deferoxamine (DFO) (Type: EXPERIMENTAL): All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Best-corrected visual acuity of at least 20/80 in both eyes~* Age above 17 years~* Use of active contraceptive methods for women in their reproductive phase of life~* Complete demographic and baseline information (Eligibility Visit)~* IOP ≥ 18 mm Hg and ≤ 36 mm Hg~* Significant visual field loss in the previous year~* Uncontrolled systemic disease~* Active ocular disease or intraocular surgery within past three months~* Use of other medications with possible substantial effect on IOP~* Allergy/contraindication to any of the study components~* Severe glaucoma according to Hodapp's criteria~* Incapacity or unwillingness to participate in the study~Exclusion Criteria:~-Any ocular illness other than mild-moderate lens loss of transparency and glaucoma/ocular hypertension

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ganfort's Group (Type: None): Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)
- Krytantek's Group (Type: None): Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess the Efficacy and Safety of DA-3002

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Turner's Syndrome through chromosome analysis~* The chronological age: 2≤AGE≤12~* The yearly growth rate should be less than 6cm; the bone age should be equal or less than 12; the height ≤ 10th percentile for the heights of their agemates~* Before the adolescence, Tuner stage I (breast)~* Normal thyroid function~Exclusion Criteria:~* Growth hormone was administered for 12 months or longer in the past~* Treated with estrogen or adrenal androgens for 12 months or longer in the past~* Malignancy, CNS Trauma, Psychiatric Disorder

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- DA-3002 (Type: EXPERIMENTAL): 0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
- Genotropin® (Type: ACTIVE_COMPARATOR): 0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Effects of Androgenicity in Aging Men and Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* males age 60-85 years~* non-diabetic fasting glucose and 2-hour oral glucose tolerance test (OGTT)~* overall good general medical health and signed informed consent~* willing to travel to West Los Angeles VA and University of California, Los Angeles in Los Angeles, California~Exclusion Criteria:~* any clinically significant abnormalities detected on screening physical exam or laboratory testing (e.g. prostate specific antigen \> 4)~* or other symptom or history of a significant underlying medical or psychiatric illness~* BMI \< 20 or \> 40~* subjects already on testosterone therapy or medications that might influence glucose regulation or hormone levels~* subjects with a history of deep venous thromboses, pulmonary embolism, breast cancer, prostate cancer, polycythemia or other contraindications to estrogen or testosterone

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- +T +E (Type: EXPERIMENTAL): +Testosterone, +Estrogen
- +T -E (Type: EXPERIMENTAL): +Testosterone, -Estrogen
- -T +E (Type: EXPERIMENTAL): -Testosterone, +Estrogen
- -T -E (Type: NO_INTERVENTION): -Testosterone, -Estrogen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1~* Expected survival ≥ 6 months.~* Histologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma.~* Documented mutation in germline BRCA1/2 or PALB2 that is predicted to be deleterious or suspected deleterious.~* Adequate organ performance based on laboratory blood tests.~* Presence of at least of one measurable lesion in agreement to RECIST criteria.~* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Patients who have received any chemotherapy for the treatment of pancreatic cancer prior to entering the study.~* Previous treatment with any poly ADP-ribose polymerase (PARP) inhibitor.~* Patients who have had radiotherapy or participated in another clinical trial with any investigational agents within 28 days of enrolment (Day 1 visit).~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin, irinotecan, 5-Fluorouracil or other agents used in the study.~* Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks of enrolment (Day 1 visit).~* Patients with known or suspected brain metastasis.~* Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment.~* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.~* Patients with myelodysplastic syndrome/acute myeloid leukaemia.~* Patients with second primary cancer except curatively treated in-situ cancer or slowly progressing malignancy.~* Known active hepatitis B or C infection.~* History of immunodeficiency (including HIV infection) or organ transplantation.~* Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluzoparib+mFOLFIRINOX (Type: EXPERIMENTAL): Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
- Placebo+mFOLFIRINOX (Type: PLACEBO_COMPARATOR): Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Larazotide Acetate to Treat Celiac Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have been diagnosed with celiac disease by biopsy for ≥ 6 months (attending physician confirmation will be accepted in lieu of a biopsy report).~* Subject must be on a gluten-free diet for at least the past 6 months.~Exclusion Criteria:~* Subject has Anti-Tissue Transglutaminase (tTG) \> 10 EU as measured by serology~* Subject intermittently consumes clinically significant quantities of non-steroidal anti-inflammatory agents (NSAIDs) and proton-pump inhibitors, within the last 3 days prior to the treatment visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Larazotide acetate (Type: EXPERIMENTAL): Larazotide acetate capsules: 12 mg QD x 3 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules: QD x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subject must be 40 years to ≤80 years of age inclusive, at the time of signing the informed consent form at Visit 1.~* COPD Diagnosis: Subjects with an established clinical history of COPD~* Screening clinical laboratory tests must be acceptable to the Investigator.~* Screening ECG must be acceptable to the Investigator~* Individual Compliance: Subjects must be willing to remain at the study center as required per protocol to complete all visit assessments~* Patients should be on scheduled maintenance treatment with one or more inhaled bronchodilator therapies.~Exclusion Criteria:~* As judged by the investigator, any evidence of significant diseases other than COPD, i.e., disease or condition which, in the investigator's opinion makes it undesirable for the subject to participate in the trial.~* Spirometry Performance:~  1. Subjects who cannot perform acceptable spirometry, i.e., meet ATS/ERS acceptability criteria.~ 2. Repeatability: Subjects who cannot perform technically acceptable spirometry in accordance with ATS repeatability criteria~* Cancer: Subjects who have cancer that has not been in complete remission for at least five years.~* Substance Abuse: Subjects, who in the opinion of the Investigator, significantly abuse alcohol or drugs~* Subjects who in the opinion of the investigator are unable to abstain from prohibited medications including LABA/LAMAs/ICS

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BGF-GFF (Type: EXPERIMENTAL): Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
- GFF-BGF (Type: EXPERIMENTAL): Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight range: 500g\~1250g~* Fetal gestational age: 23 weeks to 29 weeks~* Premature infants who cannot do spontaneous breathing, which ventilation rate is less than 12 breaths per min of ventilation rate and 25% of oxygen demand~* Premature infants who does not improve the breathing or worse within 24 hours prior to enrollment of this study~* Written consent form signed by a legal representative or a parent~Exclusion Criteria:~* Cyanotic or acyanotic congenital heart diseases except patent ductus arteriosus~* Severe lung malformation (i.e. Pulmonary hypoplasia, congenital diaphragmatic hernia, congenital cystic lung disease)~* Severe lung malformation with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc)~* Severe congenital infection (i.e. Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc)~* CRP \> 30 mg/dL; Severe sepsis or shock~* Premature infants who is going to or expected to have surgery 72 hours before/after this study drug administration~* Surfactant administration within 24 hours prior to this study drug administration~* Severe intracranial hemorrhage ≥ grade 3 or 4~* Premature infants who have active pulmonary hemorrhage or active air leak syndrome at the time point of screening~* History of other clinical studies as a participant~* Premature infants who are allergic to Gentamicin~* Premature infants who is considered inappropriate by the investigators

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- PNEUMOSTEM® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Group A (Bleeding patients)~  * Overt bleeding judged by the physician to require a reversal agent~ * Currently taking dabigatran etexilate~ * At least 18 years of age~ * Written informed consent~* Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding~  * Condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.~ * Current treatment with dabigatran~ * At least 18 years of age~ * Written Informed consent.~Exclusion criteria:~* Group A (Bleeding Patients)~  * Patients with minor bleeds (epistaxis, hematuria) who can be managed with standard supportive care.~ * Patients with no clinical signs of bleeding~ * Contraindications to study medication including known hypersensitivity to the drug or its excipients.~* Group B (Patients who require emergency surgery or procedure)~  * A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.~ * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- idarucizumab (Type: EXPERIMENTAL): idarucizumab Only 1 treatment, no placebo or comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete